Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK of ZSP1601 in Healthy Chinese Subjects
NCT03392779Phase 1Completed
- Sponsor
- Zhongsheng Pharma
- Start
- Jan 2018
- Primary completion
- Dec 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of zsp1601 in Nonalcoholic steatohepatitis (NASH) (9 arms), sponsored by Zhongsheng Pharma. Primary endpoints: Treatment-Emergent Adverse Events up to 17 days, Serious Adverse Events up to 17 days and 5 more. Started Jan 2018; status: completed.
02
Drugs
zsp1601
03
Conditions
Nonalcoholic steatohepatitis (NASH)
Beyond the preview
Go deeper on NCT03392779.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03392779.